UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 328

Sortiert nach

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

Science (American Association for the Advancement of Science), 2020-05, Vol.368 (6494)

2020

Volltextzugriff (PDF)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

Cellular & molecular immunology, 2021-09, Vol.18 (9), p.2188-2198

2021

Volltextzugriff (PDF)

Cross-presentation: underlying mechanisms and role in immune surveillance

Immunological reviews, 2005-10, Vol.207 (1), p.166-183

2005

Volltextzugriff (PDF)

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

Blood cancer journal (New York), 2022-07, Vol.12 (7), p.104-104, Article 104

2022

Volltextzugriff (PDF)

Proteases in MHC Class I Presentation and Cross-Presentation

The Journal of immunology (1950), 2010-01, Vol.184 (1), p.9-15

2010

Volltextzugriff (PDF)

Cellular Protein Is the Source of Cross-Priming Antigen in vivo

Proceedings of the National Academy of Sciences - PNAS, 2004-03, Vol.101 (9), p.3035-3040

2004

Volltextzugriff (PDF)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

Blood cancer journal (New York), 2022-06, Vol.12 (6), p.96-96, Article 96

2022

Volltextzugriff (PDF)

248 SMART CAR-T cells resist tumor immunosuppressive microenvironment with enhanced efficacy against solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A287-A287

2023

Volltextzugriff (PDF)

Protein S gene mutation c.946C > T (p.R316C) contributed to ischemic stroke in a man with von Willebrand disease type 3 caused by two novel VWF gene mutations, c.2328delT (p.A778Lfs 23) and c.6521G > T (p.C2174F)

Clinical case reports, 2022-08, Vol.10 (8), p.e6269-n/a

2022

Volltextzugriff (PDF)

P369: DONOR‐DERIVED ANTI‐CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1 TRIAL

HemaSphere, 2023-08, Vol.7 (S3), p.e5460334-n/a

2023

Volltextzugriff (PDF)

110 IL-2 variant improves CAR-T functionality and efficacy against solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A120-A120

2021

Volltextzugriff (PDF)

TLR4 is a negative regulator in noninfectious lung inflammation

The Journal of immunology (1950), 2010-05, Vol.184 (9), p.5308-5314

2010

Volltextzugriff (PDF)

S234: UPDATED CLINICAL RESULTS OF FIRST‐IN‐HUMAN STUDY OF CD19/BCMA DUAL‐TARGETING FAST CAR‐T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e3293192-n/a

2023

Volltextzugriff (PDF)

P869: UPDATED RESULTS OF A PHASE I, OPEN‐LABEL STUDY OF BCMA/CD19 DUAL‐TARGETING FASTCAR‐T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere, 2023-08, Vol.7 (S3), p.e84060bf-n/a

2023

Volltextzugriff (PDF)

Assessment of roles for calreticulin in the cross-presentation of soluble and bead-associated antigens

PloS one, 2012-07, Vol.7 (7), p.e41727-e41727

2012

Volltextzugriff (PDF)

Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management

Clinical cancer research, 2021-03, Vol.27 (5), p.1242-1246

2021

Volltextzugriff (PDF)

Exploiting T cell signaling to optimize engineered T cell therapies

Trends in cancer, 2022-02, Vol.8 (2), p.123-134

2022

Volltextzugriff (PDF)

Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies

Blood, 2021-11, Vol.138 (Supplement 1), p.1722-1722

2021

Volltextzugriff (PDF)

RNASEH1-AS1 induced by H3K27ac stabilizes ANXA2 mRNA to promote the progression of colorectal cancer through recruiting BUD13

Neoplasma, 2023-10, Vol.70 (5), p.597

2023

Volltextzugriff (PDF)

Prevalence and genotype distribution of high‐risk human papillomavirus infection among women with cervical cytological abnormalities in Chongqing, China, 2014–2020

Diagnostic cytopathology, 2021-12, Vol.49 (12), p.1237-1243

2021

Volltextzugriff (PDF)

Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7562-7562

2023

Volltextzugriff (PDF)

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8005-8005

2023

Volltextzugriff (PDF)

Photocurrent responsive supramolecular coordination networks with redox-active tetrathiafulvalene cores

Journal of solid state chemistry, 2019-02, Vol.270, p.247-251

2019

Volltextzugriff (PDF)

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.889-890

2022

Volltextzugriff (PDF)

CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies

Leukemia, 2023-11, Vol.37 (11), p.2176-2186

2023

Volltextzugriff (PDF)

1 – 25 von 328

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(308)
Mit Volltextzugriff
(319)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(220)
Life Sciences & Biomedicine
(101)
Technology
(96)
Physical Sciences
(85)
Engineering
(63)
Chemistry
(54)
Environmental Sciences
(46)
Environmental Sciences & Ecology
(46)
Engineering, Chemical
(37)
Engineering, Environmental
(37)
Materials Science
(28)
Chemistry, Physical
(25)
Animals
(24)
Adsorption
(22)
Biodegradation
(22)
Humans
(22)
Materials Science, Multidisciplinary
(21)
Water Resources
(21)
Abwasser
(19)
Electrodes
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

Cross-presentation: underlying mechanisms and role in immune surveillance

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

Proteases in MHC Class I Presentation and Cross-Presentation

Cellular Protein Is the Source of Cross-Priming Antigen in vivo

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

248 SMART CAR-T cells resist tumor immunosuppressive microenvironment with enhanced efficacy against solid tumors

Protein S gene mutation c.946C > T (p.R316C) contributed to ischemic stroke in a man with von Willebrand disease type 3 caused by two novel VWF gene mutations, c.2328delT (p.A778Lfs 23) and c.6521G > T (p.C2174F)

P369: DONOR‐DERIVED ANTI‐CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1 TRIAL

110 IL-2 variant improves CAR-T functionality and efficacy against solid tumors

TLR4 is a negative regulator in noninfectious lung inflammation

S234: UPDATED CLINICAL RESULTS OF FIRST‐IN‐HUMAN STUDY OF CD19/BCMA DUAL‐TARGETING FAST CAR‐T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA

P869: UPDATED RESULTS OF A PHASE I, OPEN‐LABEL STUDY OF BCMA/CD19 DUAL‐TARGETING FASTCAR‐T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Assessment of roles for calreticulin in the cross-presentation of soluble and bead-associated antigens

Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management

Exploiting T cell signaling to optimize engineered T cell therapies

Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies

RNASEH1-AS1 induced by H3K27ac stabilizes ANXA2 mRNA to promote the progression of colorectal cancer through recruiting BUD13

Prevalence and genotype distribution of high‐risk human papillomavirus infection among women with cervical cytological abnormalities in Chongqing, China, 2014–2020

Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)

Photocurrent responsive supramolecular coordination networks with redox-active tetrathiafulvalene cores

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies

Suchergebnisse filtern